

## INDEX

### A

- Adriamycin. *See* Doxorubicin.
- Akt signaling, as target of therapy for multiple myeloma, 1082–1083
- Alkylators, for multiple myeloma treatment, complications of, 1255
- Allogeneic stem cell transplantation, in multiple myeloma, 1165–1169
  - myeloablative conditioning regimens, 1165–1166
  - questions to be answered in the near future, 1169
  - reduced intensity conditioning regimens, 1166–1168
  - tandem autologous/reduced-intensity conditioning, 1168–1169
- Amplifications, 1q, in molecular pathogenesis of multiple myeloma, 993–994
- Anabolic agents, of bone, bortezomib as a potential for multiple myeloma, 1043–1045
- Anemia, in patients with multiple myeloma, 1234–1235
- Angiogenesis, in monoclonal gammopathy of undetermined significance, 1102
- Animal models. *See* Mouse models.
- Anthracyclines, for multiple myeloma treatment, complications of, 1262–1264
- Antigen-presenting cells, in multiple myeloma, 1220
- Arsenic trioxide, for multiple myeloma treatment, complications of, 1264–1265
- Autologous stem cell transplantation, in multiple myeloma, 1157–1165
  - double, 1159–1160
  - in management of newly diagnosed, **1141–1156**
  - novel agents as induction treatment before, 1160–1162
  - novel agents as maintenance after, 1162–1163

- novel agents in combination with, 1160
- randomized studies comparing conventional chemotherapy and, 1157–1159
- which patients benefit from, 1163–1164
- will novel agents replace, 1164–1165

### B

- B-cell activating factor, as target in therapy of multiple myeloma, 1075
- Bcl-xL, as target of therapy for multiple myeloma, 1083
- Bcl2, as target of therapy for multiple myeloma, 1083
- Bence Jones proteinuria, idiopathic, in variant of monoclonal gammopathy of undetermined significance, 1106
- Biclonal gammopathy, variant of monoclonal gammopathy of undetermined significance, 1106
- Biochemical markers, of bone turnover in multiple myeloma, 1042–1043
- Biology, of multiple myeloma, classification schemes based on, 1118–1125
- Bisphosphonates, for supportive care in multiple myeloma, complications of, 1248–1250
- Bleeding disorders, in patients with multiple myeloma, 1236–1237
- Bone anabolic agents, bortezomib as a potential, for multiple myeloma, 1043–1045
- Bone disease, as complication of multiple myeloma, 1238–1240
  - frequency, 1238–1239
  - treatment, 1240
  - in multiple myeloma, pathophysiology of, **1035–1049**
  - biochemical markers of bone turnover in, 1042–1043

Note: Page numbers of article titles are in **boldface** type.

- Bone disease (*continued*)
- increased osteoclast activity in, 1036–1039
    - interleukin-6, 1037
    - macrophage inflammatory protein-1 alpha, 1039
    - receptor activator of nuclear factor  $\kappa$ B ligand, 1037–1039
  - new approaches for treatment of, 1043–1045
    - bortezomib, 1043–1045
  - normal bone remodeling, 1035–1036
  - osteoblast inhibition in, 1039–1042
    - DKK1 and the Wnt signaling pathway, 1040–1041
    - interleukin-3, 1041–1042
    - interleukin-7, 1042
- Bone lesions, models of diffuse multiple myeloma in immunocompromised mice, 1056–1059
- Bone marrow, failure of, in patients with multiple myeloma, 1235–1236
- microenvironment of, role in multiple myeloma, **1007–1034**, 1071–1072
    - cellular constituents and extracellular components, 1008
    - future directions in therapeutic targeting of tumor-stromal interactions, 1020–1023
    - genetic substrate of
      - tumor-microenvironment interactions, 1020
    - interaction of multiple myeloma cells, functional networks of cytokines/mitogens mediating the, 1015–1016
    - signaling pathways
      - stimulated during, 1016–1017
    - with bone marrow stromal cells, 1008–1009
    - with multiple myeloma-associated bone marrow endothelial cells, 1009–1011
      - with osteoblasts, 1012–1014
      - with osteoclasts, 1011–1012
    - process of multiple myeloma cells homing to, 1014–1015
    - relative importance of IL-6, IGFs, and other cytokines in biologic behavior, 1017–1020
- Bone remodeling, normal, 1035–1036
- Bone turnover, biochemical markers of, in multiple myeloma, 1042–1043
- Bortezomib (Velcade), as induction treatment before autologous stem cell transplant for multiple myeloma, 1161–1162
- as potential bone anabolic agent in multiple myeloma, 1043–1045
- as target of therapy for multiple myeloma, 1077–1079
  - for multiple myeloma treatment, complications of, 1261–1262
  - for relapsed or refractory multiple myeloma, 1182–1198
    - combinations of lenalidomide and, 1202
      - in elderly and high-risk patients, 1205–1206
      - in patients with renal dysfunction, 1204–1205
      - rational design of combinations with, 1203–1204
    - in regimens for newly diagnosed multiple myeloma in patients eligible for transplant, 1148
    - with melphalan and prednisone, for newly diagnosed multiple myeloma in patients not eligible for transplant, 1152
- 
- C**
- CD40, as target in therapy of multiple myeloma, 1076
- Cell-mediated responses, in multiple myeloma, 1219
- Chemotherapy, conventional, studies comparing with autologous stem cell transplantation for multiple myeloma, 1157–1159
- in patients with multiple myeloma and renal failure, 1233
  - or multiple myeloma, complications of, 1254–1265
    - alkylators, 1255
    - anthracyclines, 1262–1264
    - arsenic trioxide, 1264–1265
    - bortezomib, 1261–1262
    - corticosteroids, 1262
    - lenalidomide, 1257–1261
    - thalidomide, 1255–1257
    - vincristine, 1264
- Chromosome 1 abnormalities, in biologic classification of multiple myeloma, 1122–1123
- Chromosome 13 deletions, in molecular pathogenesis of multiple myeloma, 994–995

- Classification, of multiple myeloma, schemes based on biology, 1118–1125
- Complications, of multiple myeloma, **1231–1246**
- bone complications, 1238–1240
  - hematologic complications, 1234–1237
  - infectious complications, 1237–1238
  - neurologic complications, 1240–1243
  - renal sufficiency, 1231–1234
  - of therapy for multiple myeloma, **1247–1273**
  - chemotherapy, 1254–1265
    - alkylators, 1255
    - anthracyclines, 1262–1264
    - arsenic trioxide, 1264–1265
    - bortezomib, 1261–1262
    - corticosteroids, 1262
    - lenalidomide, 1257–1261
    - thalidomide, 1255–1257
    - vincristine, 1264
  - supportive care, 1247–1254
    - bisphosphonates, 1248–1250
    - erythropoiesis-stimulating agents, 1250–1254
- Conditioning regimens, for allogeneic stem cell transplant in multiple myeloma, 1165–1169
- myeloablative, 1165–1166
  - reduced-intensity, 1166–1168
  - reduced-intensity, with tandem autologous transplant, 1168–1169
- Connective tissue disorders, association of monoclonal gammopathy of undetermined significance with, 1107
- Corticosteroids, for multiple myeloma treatment, complications of, 1262
- Cyclins, translocations affecting, in multiple myeloma pathogenesis, 990
- Cytokines, in biologic behavior of multiple myeloma cells in the bone marrow milieu, 1017–1020
- myeloma bone disease associated, in monoclonal gammopathy of undetermined significance, 1102
  - role in mediating interactions between tumor and stroma in multiple myeloma, 1015–1016
- 
- D**
- Death, cause of, in monoclonal gammopathy of undetermined significance, 1103
- Deletions, of 17p13, in biologic classification of multiple myeloma, 1121–1122
- Dendritic cells, idiotype-pulsed, clinical trials in multiple myeloma, 1224–1225
- Dermatologic diseases, association of monoclonal gammopathy of undetermined significance with, 1109
- Dexamethasone, for newly diagnosed multiple myeloma in patients eligible for transplant, 1145–1148
- lenalidomide and, 1147–1148
  - thalidomide and, 1145–1147
- for relapsed or refractory multiple myeloma, high-dose, 1176
- with doxorubicin and vincristine, 1176–1177
  - with vincristine and adriamycin, for induction treatment before autologous stem cell transplant for multiple myeloma, 1160–1161
- Dialysis, in patients with multiple myeloma and renal failure, 1234
- DKK1, and Wnt signaling pathway in multiple myeloma, 1040–1041
- DNA ploidy status, and prognosis in multiple myeloma, 1125–1126
- Doxorubicin, with vincristine and dexamethasone, for induction treatment before autologous stem cell transplant for multiple myeloma, 1160–1161
- for relapsed or refractory multiple myeloma, 1176–1177
- 
- E**
- Elderly patients, novel agents in treatment of relapsed multiple myeloma in, 1204–1205
- Endocrine disorders, association of monoclonal gammopathy of undetermined significance with, 1109
- Endothelial cells, multiple myeloma-associated bone marrow, interactions of multiple myeloma cells with, 1009–1011
- Erythropoiesis-stimulating agents, for supportive care in multiple myeloma, complications of, 1250–1254
- 
- F**
- Fibroblast growth factor (FGF), as target in therapy of multiple myeloma, 1075
- Fibroblast growth factor receptor 3, in multiple myeloma pathogenesis, 990
- Fractures, pathologic, as complication of multiple myeloma, 1239
- 
- G**
- Gains, 1q, in molecular pathogenesis of multiple myeloma, 993–994

- Gammopathy. *See* Monoclonal gammopathy of undetermined significance (MGUS).
- Genetic changes, in monoclonal gammopathy of undetermined significance, 1101–1102
- Genetic lesions, in multiple myeloma, overview of, 985–988
- Genetic models, of multiple myeloma, 1061–1063
- Growth factors, and receptors as targets for multiple myeloma therapy, 1072–1076
  - B-cell activating factor, 1075
  - CD40, 1076
  - FGF, 1075
  - insulin-like growth factor-1, 1073–1074
  - interleukin-6, 1072–1073
  - others, 1076
  - vascular endothelial growth factor, 1074
  - Wnt, 1075–1076
- H**
- Heat shock protein, as target of therapy for multiple myeloma, 1082
- Helicobacter pylori*, in monoclonal gammopathy of undetermined significance, 1102
- Hematologic complications, of multiple myeloma, 1234–1237
  - anemia, 1234–1235
  - bone marrow failure, 1235–1236
  - hyperviscosity syndrome and bleeding disorders, 1236–1237
- High-risk patients, novel agents in treatment of relapsed multiple myeloma in, 1204–1205
- Histone deacetylase, as target of therapy for multiple myeloma, 1080–1082
  - LBH589, 1081
  - MVP-LAQ824 (LAQ824), 1081
  - others, 1081–1082
  - suberoylanilide hydroxamic acid, 1080–1081
- Hypercalcemia, as complication of multiple myeloma, 1239–1240
- Hyperdiploid multiple myeloma, 989
- Hyperviscosity syndrome, in patients with multiple myeloma, 1236–1237
- I**
- Idiotype-pulsed dendritic cells, clinical trials in multiple myeloma, 1224–1225
- IgD monoclonal gammopathy of undetermined significance, 1106
- Immune therapies, for multiple myeloma, 1217–1230
  - clinical trials, 1222–1224
    - idiotype-based clinical results, 1222–1224
    - in vivo experiments, 1221
    - preclinical studies, 1221–1222
  - future directions, 1225–1226
  - idiotype-pulsed dendritic cell trials, 1224–1225
  - immunobiology in, 1219–1222
    - antigen-presenting cells, 1220
    - cell-mediated responses, 1219–1220
    - regulatory T cells, 1220
    - T<sub>H</sub>17 cells, 1221
  - interactions between immune cells and multiple myeloma cells, 1218–1219
  - obstacles to, 1217–1218
- Immunobiology, in multiple myeloma, 1219–1222
  - antigen-presenting cells, 1220
  - cell-mediated responses, 1219–1220
  - regulatory T cells, 1220
  - T<sub>H</sub>17 cells, 1221
- Immunocompromised mice, models of diffuse multiple myeloma bone lesions in, 1056–1059
- Immunoglobulin, types of, and progression in monoclonal gammopathy of undetermined significance, 1103
- Immunomodulatory Thal derivatives (IMiDs), *See* Lenalidomide.
- Immunophenotype, and prognosis in multiple myeloma, 1126–1127
- Immunosuppression, association of monoclonal gammopathy of undetermined significance with, 1109
- Induction treatment, before autologous stem cell transplant for multiple myeloma, novel agents as, 1160–1162
- Infectious complications, in patients with multiple myeloma, 1237–1238
  - incidence and timing, 1237
  - microbiology and sites of, 1237–1238
  - treatment and prophylaxis, 1238
- Insulin-like growth factors (IGFs), in biologic behavior of multiple myeloma cells in the bone marrow milieu, 1017–1020
- IGF-1, as target in therapy of multiple myeloma, 1073–1074

- Interleukin-3 (IL-3), and osteoblast inhibition in multiple myeloma, 1041–1042
- Interleukin-6 (IL-6), and increased osteoclast activity in multiple myeloma, 1037  
as target in therapy of multiple myeloma, 1072–1073  
in biologic behavior of multiple myeloma cells in the bone marrow milieu, 1017–1020
- Interleukin-7 (IL-7), and osteoblast inhibition in multiple myeloma, 1041–1042
- Intracellular molecules, as target of therapy for multiple myeloma, 1076–1079  
bortezomib, 1077–1079  
proteasome, 1076–1077

**L**

- LAGλ-1 models, of multiple myeloma, 1061
- LAQ824, as target of therapy for multiple myeloma, 1081
- LBH589, as target of therapy for multiple myeloma, 1081
- Lenalidomide (Revlimid), as induction treatment before autologous stem cell transplant for multiple myeloma, 1162  
as target of therapy for multiple myeloma, 1076–1083  
for multiple myeloma treatment, complications of, 1257–1261  
for relapsed or refractory multiple myeloma, 1199–1204  
combinations with bortezomib and, 1202  
in combinations with chemotherapy, 1201–1202  
in elderly and high-risk patients, 1205–1206  
in patients with renal dysfunction, 1204–1205  
rational design of combinations with, 1203–1204  
with dexamethasone, for newly diagnosed multiple myeloma in patients eligible for transplant, 1147–1148  
with melphalan and prednisone, for newly diagnosed multiple myeloma in patients not eligible for transplant, 1152–1153
- Leptomeningeal involvement, as complication of multiple myeloma, 1241–1242
- Leukemia, association of monoclonal gammopathy of undetermined significance with, 1107

- Life expectancy, in monoclonal gammopathy of undetermined significance, 1103
- Lymphoproliferative disorders, association of monoclonal gammopathy of undetermined significance with, 1107

**M**

- Macrophage inflammatory protein-1 alpha, and increased osteoclast activity in multiple myeloma, 1039
- MAF translocations, in molecular pathogenesis of multiple myeloma, 991–992
- MAFB translocations, in molecular pathogenesis of multiple myeloma, 991–992
- Maintenance therapy, new approaches to, in newly diagnosed multiple myeloma in patients eligible for transplant, 1149  
novel agents as, after autologous stem cell transplant for multiple myeloma, 1162–1163
- Mammalian target of rapamycin, as target of therapy for multiple myeloma, 1083
- MAPK kinase, as target of therapy for multiple myeloma, 1083
- Melphalan, high-dose, for relapsed or refractory multiple myeloma, 1177–1179  
in regimens for newly diagnosed multiple myeloma patients not eligible for transplant, 1150–1153  
with prednisone and bortezomib, 1152  
with prednisone and lenalidomide, 1152–1153  
with prednisone and thalidomide, 1150–1152
- Microenvironment, bone marrow, role in multiple myeloma pathophysiology, **1007–1034**, 1071–1072
- Mitogens, role in mediating interactions between tumor and stroma in multiple myeloma, 1015–1016
- Models. *See* Mouse models.
- Molecular pathogenesis, of multiple myeloma, **985–1006**  
additional focal genetic lesions, 992–993  
evolution from monoclonal gammopathy of undetermined origin to, 988–989  
hyperdiploid, 989  
non-hyperdiploid, 989–992

- Molecular pathogenesis (*continued*)
- MAF and MAB
    - translocations, 991–992
  - t(4;14) and fibroblast growth factor receptor 3, 990–991
  - translocations affecting cyclins, 990
  - other genetic lesions associated with progression and prognosis, 993–998
    - 1q gains/amplifications, 993–994
    - chromosome 13 deletions, 994–995
    - minimal common regions
      - linked to poor survival, 995
    - MYC alterations, 997
    - P18 and other members of the RB1 pathway, 997–998
    - RAS mutations, 997
    - TP53 deletion and mutations, 995–997
  - overview of genetic lesions in, 985–988
- Monoclonal gammopathy of undetermined significance (MGUS), association with other disorders, 1106–1109
  - connective tissue disorders, 1107
  - dermatologic diseases, 1109
  - endocrine disorders, 1109
  - immunosuppression, 1109
  - leukemia, 1107
  - lymphoproliferative disorders, 1107
  - miscellaneous conditions, 1109
  - neurologic disorders, 1107–1108
  - other hematologic disorders, 1107
  - POEMS syndrome (osteosclerotic myeloma), 1108
  - differential diagnosis, 1103–1104
  - life expectancy and cause of death, 1103
  - long-term natural history of, 1095–1100
  - management, 1105
  - molecular basis of evolution to multiple myeloma, 988–989
  - pathophysiology of progression of, 1100–1102
    - angiogenesis, 1102
    - genetic changes, 1101–1102
    - Helicobacter pylori*, 1102
    - myeloma bone disease associated cytokines, 1102
  - predictors of progression of, 1102–1103
    - abnormal serum/FLC ratio, 1103
    - number of bone marrow plasma cells, 1103
    - size of monoclonal protein, 1102–1103
    - types of immunoglobulin, 1103
  - prevalence of, 1094
  - recognition of, 1093–1094
  - smoldering (asymptomatic) multiple myeloma and, 1109–1110
  - variants of, 1105–1106
    - biclonal gammopathy, 1106
    - idiopathic Bence Jones protein, 1106
    - IgD, 1106
    - triclonal gammopathy, 1106
- Monoclonal protein, size of, and progression in monoclonal gammopathy of undetermined significance, 1102–1103
- Morphology, and prognosis in multiple myeloma, 1126
- Mouse models, of multiple myeloma, **1051–1069**
  - diffuse bone lesions in immunocompromised mice, 1056–1059
  - genetic models of, 1061–1063
  - LAG $\lambda$ -1 model, 1061
  - models of the 5T series, 1059–1061
  - SCID-HU model, 1053–1056
  - subcutaneous xenografts of cell lines, 1052–1053
- Multiple myeloma. *See* Myeloma, multiple.
- MVP-LAQ824, as target of therapy for multiple myeloma, 1081
- MYC alterations, in molecular pathogenesis of multiple myeloma, 997
- Myeloablative conditioning regimens, for allogeneic stem cell transplant in multiple myeloma, 1165–1166
- Myeloma, multiple, bone disease in, pathophysiology of, **1035–1049**
  - biochemical markers of bone turnover in, 1042–1043
  - increased osteoclast activity in, 1036–1039
  - new approaches for treatment of, 1043–1045
  - normal bone remodeling, 1035–1036
  - osteoblast inhibition in, 1039–1042
- complications of, **1231–1246**
  - bone complications, 1238–1240
  - hematologic complications, 1234–1237
  - infectious complications, 1237–1238

- neurologic complications, 1240–1243
  - renal sufficiency, 1231–1234
  - complications of therapy for, **1247–1273**
    - chemotherapy, 1254–1265
    - supportive care, 1247–1254
  - immune therapies for, **1217–1230**
    - clinical trials, 1222–1224
    - future directions, 1225–1226
    - idiotype-pulsed dendritic cell trials, 1224–1225
    - immunobiology in, 1219–1222
    - interactions between immune cells and multiple myeloma cells, 1218–1219
    - obstacles to, 1217–1218
  - molecular pathogenesis of, **985–1006**
    - additional focal genetic lesions, 992–993
    - evolution from monoclonal gammopathy of undetermined origin to, 988–989
    - hyperdiploid, 989
    - non-hyperdiploid, 989–992
    - other genetic lesions associated with progression and prognosis, 993–998
    - overview of genetic lesions in, 985–988
  - monoclonal gammopathy of undetermined significance and, association with other disorders, 1106–1109
  - differential diagnosis, 1103–1104
  - long-term natural history of, 1095–1100
  - management, 1105
  - pathophysiology of progression of, 1100–1102
  - predictors of progression of, 1102–1103
    - life expectancy and cause of death, 1103
  - prevalence of, 1094
  - recognition of, 1093–1094
  - smoldering (asymptomatic) multiple myeloma and, 1109–1110
  - variants of, 1105–1106
- mouse models of, **1051–1069**
    - diffuse bone lesions in immunocompromised mice, 1056–1059
    - genetic models of, 1061–1063
    - LAG $\lambda$ -1 model, 1061
    - models of the 5T series, 1059–1061
    - SCID-HU model, 1053–1056
    - subcutaneous xenografts of cell lines, 1052–1053
  - newly diagnosed, management of, **1141–1156**
    - in patients eligible for transplantation, 1142–1148
    - in patients not eligible for autologous stem cell transplantation, 1149–1153
    - new maintenance approaches, 1149
    - risk stratification, 1142
    - transplantation in, 1148–1149
  - pathophysiology of, role of bone marrow microenvironment in, **1007–1034**
  - prognostic factors and staging in, **1115–1140**
    - classification schemes based on biology of, 1118–1125
    - host factors and their interactions, 1127–1130
    - other prognostic factors intrinsic to the cell, 1125–1127
    - response to initial treatment, 1130–1131
    - systems for, 1116–1118
  - relapsed and relapsed refractory, **1175–1215**
    - conventional treatment approaches, 1176–1179
      - doxorubicin, vincristine, and dexamethasone, 1176–1177
      - high-dose dexamethasone, 1176
      - high-dose melphalan, 1177–1179
    - novel agents, 1179–1206
      - bortezomib, 1182–1198
      - in elderly and high-risk patients, 1205–1206
      - in patients with renal dysfunction, 1204–1205
      - lenalidomide, 1199–1204
      - thalidomide, 1179–1182
  - smoldering, 1109–1110
  - stem cell transplantation for, **1157–1174**
    - allogeneic, 1165–1169
    - autologous, 1157–1165
  - targeted therapies of, preclinical studies of, **1071–1091**
    - growth factors and their receptors, 1072–1076
      - B-cell activating factor, 1075
      - CD40, 1076
      - FGF, 1075

Myeloma (*continued*)

- insulin-like growth factor-1, 1073–1074
- interleukin-6, 1072–1073
- others, 1076
- vascular endothelial growth factor, 1074
- Wnt, 1075–1076
- intracellular molecules, 1076–1079
  - bortezomib, 1077–1079
  - proteasome, 1076–1077
- proteasome inhibitors, 1079–1083
  - Akt (protein kinase B), 1082–1083
  - heat shock protein 90, 1082
  - histone deacetylase, 1080–1082
  - lenalidomide, 1079–1080
  - mammalian target of rapamycin, 1083
  - MAPK kinase, 1083
- role of bone marrow microenvironment in, 1071–1072

**N**

- Nerve root compression, as complication of multiple myeloma, 1241
- Neurologic complications, of multiple myeloma, 1240–1243
  - intracranial plasmacytomas, 1241
  - leptomeningeal involvement, 1241–1242
  - nerve root compression, 1241
  - neuropathies associated with neurotoxic drugs, 1243
  - peripheral neuropathy, 1242–1243
  - spinal cord compression, 1241
- Neurologic disorders, association of monoclonal gammopathy of undetermined significance with, 1107–1108
- Neuropathy, as complication of multiple myeloma, associated with neurotoxic drugs, 1243
  - peripheral, 1242–1243
- Non-hyperdiploid multiple myeloma, 989–992
  - MAF and MAB translocations, 991–992
  - t(4;14) and fibroblast growth factor receptor 3, 990–991
  - translocations affecting cyclins, 990
- Nuclear factor- $\kappa$ B, non canonical activation, in biologic classification of multiple myeloma, 1123
  - receptor activator of, and increased osteoclast activity in multiple myeloma, 1037–1039

**O**

- Osteoblasts, inhibition in multiple myeloma, 1039–1042
  - DKK1 and the Wnt signaling pathway, 1040–1041
  - interleukin-3, 1041–1042
  - interleukin-7, 1042
  - interactions with multiple myeloma cells, 1012–1014
- Osteoclasts, activity in multiple myeloma, 1036–1039
  - interleukin-6, 1037
  - macrophage inflammatory protein-1 alpha, 1039
  - receptor activator of nuclear factor  $\kappa$ B ligand, 1037–1039
  - interactions with multiple myeloma cells, 1011–1012
- Osteosclerotic myeloma (POEMS syndrome), association of monoclonal gammopathy of undetermined significance with, 1108

**P**

- p16 methylation, and Ras mutation, in biologic classification of multiple myeloma, 1122
- P18, in molecular pathogenesis of multiple myeloma, 997–998
- Pathogenesis, of multiple myeloma, molecular. *See* Molecular pathogenesis.
- Pathophysiology, of multiple myeloma, role of bone marrow microenvironment in, **1007–1034**
  - cellular constituents and extracellular components, 1008
  - future directions in therapeutic targeting of tumor-stromal interactions, 1020–1023
  - genetic substrate of tumor-microenvironment interactions, 1020
  - interaction of multiple myeloma cells, functional networks of cytokines/mitogens mediating the, 1015–1016
  - signaling pathways
    - stimulated during, 1016–1017
  - with bone marrow stromal cells, 1008–1009
  - with multiple myeloma-associated bone marrow endothelial cells, 1009–1011
  - with osteoblasts, 1012–1014



- with osteoclasts, 1011–1012
    - process of multiple myeloma cells homing to, 1014–1015
    - relative importance of IL-6, IGFs, and other cytokines in biologic behavior, 1017–1020
  - Peripheral neuropathy, as complication of multiple myeloma, 1242–1243
  - Plasma cells, proliferative activity of, and prognosis in multiple myeloma, 1125–1126
  - Plasma exchange, in patients with multiple myeloma and renal failure, 1234
  - Plasmacytoma, intracranial, as complication of multiple myeloma, 1241
  - POEMS syndrome, association of monoclonal gammopathy of undetermined significance with, 1108
  - Preclinical studies, of novel targeted therapies for multiple myeloma, **1071–1091**
  - Predictive factors, in biologic classification of multiple myeloma, 1123–1124
  - Prednisone, in regimens for newly diagnosed multiple myeloma patients not eligible for transplant, 1150–1153
    - with melphalan and bortezomib, 1152
    - with melphalan and lenalidomide, 1152–1153
    - with melphalan and thalidomide, 1150–1152
  - Prognostic factors, and staging in multiple myeloma, **1115–1140**
    - classification schemes based on biology of, 1118–1125
    - host factors and their interactions, 1127–1130
    - other prognostic factors intrinsic to the cell, 1125–1127
      - DNA ploidy status and proliferative activity of plasma cells, 1125–1126
      - immunophenotype, 1126–1127
      - morphology, 1126
      - response to initial treatment, 1130–1131
      - systems for, 1116–1118
  - Proliferative activity, of plasma cells, and prognosis in multiple myeloma, 1125–1126
  - Proteasome inhibitors, as target of therapy for multiple myeloma, 1076–1083
  - Protein kinase B, as target of therapy for multiple myeloma, 1082–1083
  - Protein, monoclonal, size of, and progression in monoclonal gammopathy of undetermined significance, 1102–1103
- 
- R**
- Ras mutation, and p16 methylation, in biologic classification of multiple myeloma, 1122
  - RAS mutations, in molecular pathogenesis of multiple myeloma, 997
  - RB1 pathway, in molecular pathogenesis of multiple myeloma, 997–998
  - Refractory multiple myeloma. *See under* Relapsed multiple myeloma.
  - Regulatory T cells, in multiple myeloma, 1220
  - Relapsed multiple myeloma, and relapsed refractory, **1175–1215**
    - conventional treatment approaches, 1176–1179
      - doxorubicin, vincristine, and dexamethasone, 1176–1177
      - high-dose dexamethasone, 1176
      - high-dose melphalan, 1177–1179
    - novel agents, 1179–1206
      - bortezomib, 1182–1198
      - in elderly and high-risk patients, 1205–1206
      - in patients with renal dysfunction, 1204–1205
      - lenalidomide, 1199–1204
      - thalidomide, 1179–1182
  - Renal dysfunction, novel agents in treatment of relapsed multiple myeloma in patients with, 1204–1205
  - Renal insufficiency, as complication of multiple myeloma, 1231–1234
    - frequency, 1231
    - pathogenesis, 1231–1232
    - reversibility of, 1232–1233
    - supportive measures, 1234
    - treatment approaches, 1233–1234
  - Renal transplantation, in patients with multiple myeloma and renal failure, 1233–1234

Response, to initial treatment, and prognosis in multiple myeloma, 1130–1131  
 Revlimid. *See* Lenalidomide.

## S

SCID-HU model, of multiple myeloma, 1053–1056

Signaling pathways, stimulated in multiple myeloma cells during interaction with local environment, 1016–1017

Smoldering multiple myeloma, 1109–1110  
 natural history, 1109–1110  
 therapy, 1110

Spinal cord compression, as complication of multiple myeloma, 1239, 1241

Staging, prognostic factors and, in multiple myeloma, **1115–1140**  
 classification schemes based on biology of, 1118–1125  
 host factors and their interactions, 1127–1130  
 other prognostic factors intrinsic to the cell, 1125–1127  
 response to initial treatment, 1130–1131  
 systems for, 1116–1118

Stem cell transplantation, allogeneic, in multiple myeloma, 1165–1169  
 myeloablative conditioning regimens, 1165–1166  
 questions to be answered in the near future, 1169  
 reduced intensity conditioning regimens, 1166–1168  
 tandem autologous/reduced-intensity conditioning, 1168–1169  
 autologous, in multiple myeloma, 1157–1165  
 in management of newly diagnosed, **1141–1156**  
 novel agents as induction treatment before, 1160–1162  
 novel agents as maintenance after, 1162–1163  
 novel agents in combination with, 1160  
 randomized studies comparing conventional chemotherapy and, 1157–1160  
 which patients benefit from, 1163–1164  
 will novel agents replace, 1164–1165

Subcutaneous xenografts, of multiple myeloma cell lines, 1052–1053

Suberoylanilide hydroxamic acid, as target of therapy for multiple myeloma, 1080–1081

Supportive care, for multiple myeloma, complications of, 1247–1254  
 bisphosphonates, 1248–1250  
 erythropoiesis-stimulating agents, 1250–1254

## T

T cells, regulatory, in multiple myeloma, 1220

t(4;14), and multiple myeloma set domain, 990–991

Tandem autologous/reduced-intensity conditioning allogeneic transplants, for multiple myeloma, 1168–1169

Targeted therapies, for multiple myeloma, preclinical studies of novel, **1071–1091**  
 growth factors and their receptors, 1072–1076  
 B-cell activating factor, 1075  
 CD40, 1076  
 FGF, 1075  
 insulin-like growth factor-1, 1073–1074  
 interleukin-6, 1072–1073  
 others, 1076  
 vascular endothelial growth factor, 1074  
 Wnt, 1075–1076  
 intracellular molecules, 1076–1079  
 bortezomib, 1077–1079  
 proteasome, 1076–1077  
 proteasome inhibitors, 1079–1083  
 Akt (protein kinase B), 1082–1083  
 heat shock protein 90, 1082  
 histone deacetylase, 1080–1082  
 lenalidomide, 1079–1080  
 mammalian target of rapamycin, 1083  
 MAPK kinase, 1083  
 role of bone marrow microenvironment in, 1071–1072  
 tumor-stromal interactions in multiple myeloma, future therapeutic targeting of, 1020–1023

T<sub>H</sub>17 cells, in multiple myeloma, 1221

Thalidomide, as induction treatment before autologous stem cell transplant for multiple myeloma, 1160–1162

- as maintenance after autologous stem cell transplant for multiple myeloma, 1162–1163
  - for multiple myeloma treatment, complications of, 1255–1257
  - for newly diagnosed multiple myeloma, with dexamethasone, in patients eligible for transplant, 1145–1147
    - with melphalan and prednisone, in patients not eligible for transplant, 1150–1152
  - for relapsed or refractory multiple myeloma, 1179–1182
    - combining chemotherapy and, 1181–1182
    - in elderly and high-risk patients, 1205–1206
    - in patients with renal dysfunction, 1204–1205
    - single-agent, 1179–1180
      - with dexamethasone, 1180–1181
  - TP53 deletion, and mutations in molecular pathogenesis of multiple myeloma, 995–997
  - Transplantation, renal, in patients with multiple myeloma and renal failure, 1233–1234
    - stem cell. *See* Stem cell transplantation.
  - Triclonal gammopathy, variant of monoclonal gammopathy of undetermined significance, 1106
- 
- V**
- Vascular endothelial growth factor, as target in therapy of multiple myeloma, 1074
  - Velcade. *See* Bortezomib.
  - Vincristine, for multiple myeloma treatment, complications of, 1264
    - for relapsed or refractory multiple myeloma, with doxorubicin and dexamethasone, 1176–1177
    - with adriamycin and dexamethasone, for induction treatment before autologous stem cell transplant for multiple myeloma, 1160–1161
- 
- W**
- Wnt, as target in therapy of multiple myeloma, 1075–1076
  - Wnt signaling pathway, DKK1 and, in multiple myeloma, 1040–1041
- 
- X**
- Xenografts, subcutaneous, of multiple myeloma cell lines, 1052–1053